Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy

Nuclear Medicine Communications

Volumn 25, Issue 8, 2004, Pages 799-805

  Haq, Masud S ^a   McCready, Ralph V ^a   Harmer, Clive L ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Differentiated thyroid carcinoma; High activity; Radioiodine therapy; Toxicity

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METASTASIS; MORBIDITY; RADIOIODINATION; RETROSPECTIVE STUDY; SALIVARY GLAND DISEASE; STANDARDIZATION; THYROID CARCINOMA; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COMORBIDITY; FEMALE; GREAT BRITAIN; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 4143094738     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000136693.94761.5c     Document Type: Article

References (27)

1. Vini L, Harmer C. Radioiodine treatment for differentiated thyroid cancer. Clin Oncol 2000; 12:365-372.
2. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch C. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39:1551-1554.
3. Grunwald F, Ruhlmann J, Amman B, Knopp R, Hotze A, Biersack H. Experience with a high dose therapy concept in metastatic differentiated thyroid cancer. Nuclear Medizin 1988; 27:266-271.
4. Menzel C, Grünwald F, Schomburg A, Palmedo H, Bender H, Spath G, Biersack H-J. ‘High-dose’ radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996; 37:1496-1503.
5. Pelikan DM, Lion HL, Hermans J, Goslings BM. The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma. Clin Endocrinol 1997; 47:713-720.
6. Harmer C, Bidmead M, Shepherd S, Shame A, Vini L. Radiotherapy planning techniques for thyroid cancer. Br J Radiol 1998; 71:1069-1075.
7. Protopapas A, Nicholson A, Vini L, Harmer C, Goldstraw P. Thoracic metastasectomy in thyroid malignancies. Ann Thorac Surg 2001; 72:1906-1908.
8. Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges P, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002; 29:775-782.
9. Miller A, Hooggstraten B, Staques M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
10. Varma V, Beierwaltes W, Nofal M, Mishiyama R, Copp J. Treatment of thyroid cancer-death rates after surgery and after surgery followed by sodium iodide 131. J Am Med Assoc 1970; 214:1437-1442.
11. Schlumberger M, Tubiana M, Vathaire F, Hill C, Gardet P, Travagli J, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Med 1986; 63:960-967.
12. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 1984; 57:323-327.
13. Petrich T, Widjaja A, Musholt TJ, Hofmann M, Brunkhorst T, Ehrenheim C, et al. Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. Eur J Nucl Med 2001; 28:203-208.
14. Mazzaferri E, Jhiang S. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418-428.
15. Keldsen N. Haematological effects from radioiodine treatment of thyroid cancer. Acta Oncol 1990; 29:1035-1039.
16. Grünwald F, Schomburg A, Menzel C, Steinecker S, Späth S, Bokisch A, et al. Blood count changes after radioiodine treatment in thyroid carcinoma. Med Klin 1994; 89:522-528.
17. Bohuslaviskj K, Klutmann S, Brenner W, Mester J, Henze E, Clausen M. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo controlled study. J Clin Oncol 1998; 16:3542-3549.
18. Hyer S, Vini L, O'Connell M, Pratt B, Harmer C. Testicular dose and fertility in men following I-131 therapy for thyroid cancer. Clin Endocrinol 2002; 56:755-758.
19. Vini L, Hyer S, Al Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 2002; 78:92-93.
20. Maxon H, Smith H. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19:685-718.
21. Rubino C, De Vathaire F, Dottorini M, Hall P, Schuartz C, Lovette J. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89:1638-1644.
22. Rall J, Alpers J, Lewallen C, Sonenborg M, Berman M, Rawson R. Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol Metab 1957; 17:1263-1276.
23. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Radiol 1962; 87:171-182.
24. O'Connell MEA, Flower MA, Hinton PJ, Harmer CL, McCready VR. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol 1993; 28:16-26.
25. Mazzaferri F, Kloos R. Using recombinant human TSH in the management of well differentiated thyroid cancer: current strategies and future directions. Thyroid 2000; 10:767-778.
26. Robbins J, Tuttle M, Sonenberg M, Shaha A, Sharaf R, Robbins H, et al. Radioiodine ablation of thyroid remnants after preparation with recomb inant human thyrotropin. Thyroid 2001; 11:865-869.
27. 131I therapy of metastatic well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84:912-916.